Manchester Royal Eye Hospital

Manchester, United Kingdom

Manchester Royal Eye Hospital

Manchester, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Yu J.T.S.,Manchester Royal Eye Hospital
Ophthalmic Plastic and Reconstructive Surgery | Year: 2017

A 54-year-old woman received multiple injections of hyaluronic acid filler to the brow region to address volume loss over a 21-month period. She then developed significant pitting edema of both upper eyelids, which persisted for 6 years. Hyaluronidase (Hyalase) was injected into the subcutaneous brows and resulted in complete resolution of the edema within 2 days. This confirms that the hyaluronic acid injected into the brows was responsible for this patient’s chronic eyelid edema. This case illustrates an unusual long-term complication of periocular hyaluronic acid filler. © 2017 by The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc., All rights reserved.


SYLMAR, Californie, et LAUSANNE, Suisse--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (Nasdaq : EYES) (« Second Sight »), société qui conçoit, développe et commercialise des prothèses visuelles implantables permettant de restituer une partie de la fonction visuelle chez des patients non-voyants, annonce aujourd’hui que le NHS, système de santé publique du Royaume-Uni, remboursera le traitement de son système de prothèse rétinienne, l’« œil bionique » Argus® II pour des patients aveugles atteints de rétinite pigmentaire (RP). Ce remboursement est une première au Royaume-Uni et fait suite à la recommandation positive d’un groupe de conseillers aux autorités de financement des soins de santé du Gouvernement britannique pour les services spécialisés en Angleterre. NHS England a annoncé que certains patients atteints de cécité sévère due à une rétinite pigmentaire pourront avoir accès à l’Argus II, premier et unique traitement au monde ayant obtenu les autorisations commerciales en Europe et aux Etats-Unis pour ce type de cécité. Il sera disponible dans deux centres d’implantation : le Manchester Royal Eye Hospital pour le nord de l’Angleterre et le Moorfields Eye Hospital à Londres. Ces deux hôpitaux et la société Second Sight mettront sur pied le suivi, la rééducation et le support adéquat aux patients recevant un implant Argus II. Le système Argus II sera financé via le programme Commissioning through Evaluation (CtE), un programme spécialement conçu pour donner l’accès à des traitements prometteurs tout en collectant davantage de données cliniques dans le cadre d’un programme d’évaluation officiel. Argus II est déjà remboursé en France via le « Forfait Innovation », programme de prise en charge dérogatoire et transitoire, dans le cadre duquel les patients peuvent bénéficier du traitement avec Argus II. Will McGuire, président et PDG de Second Sight, affirme : « Il s’agit d’une étape importante pour Second Sight car nous sommes la seule société capable de démontrer un bilan bénéfice-risque favorable sur le long terme, jusqu’à cinq ans après implantation pour certains patients atteints de RP. On sait que le NHS England est soumis à d’importantes pressions financières et également très sélectif dans l’adoption de technologies innovantes – qui doivent démontrer un rapport qualité-prix suffisant. Nous nous attendons à ce que cette décision soit considérée par d’autres services de soins de santé dans le monde. » Le Professeur Paulo Stanga du Manchester Royal Eye Hospital, de l’Université de Manchester et du Manchester Vision Regeneration (MVR) Lab au NIHR/Wellcome Trust Manchester Clinical Research Facility, qui a joué un rôle crucial pour que les patients aient accès à l’« œil bionique » au NHS, déclare : « Je suis ravi que notre étude sur ce dispositif innovant ait pu fournir la preuve pour soutenir la décision du NHS England de financer l’« œil bionique » pour la première fois. J'ai été en première ligne pour constater à quel point cette technologie était bénéfique et changeait la vie de patients atteints de RP et complètement non-voyants. Nous vivons dans un monde visuel, il est donc rassurant et enthousiasmant pour une personne entièrement aveugle de récupérer des perceptions visuelles. Il s’agit d’une décision formidable. Pour les familles de patients, c’est également un traitement améliorant les conditions de vie, car cela peut signifier moins de dépendance pour leurs proches. » Le Professeur Lyndon da Cruz, MD, PhD, chirurgien consultant de la rétine au Moorfields Eye Hospital NHS Foundation Trust qui, avec le Professeur Stanga, a défendu pendant plus de cinq ans le remboursement du traitement par le NHS, déclare : « Pour les patients souffrant de RP avec une perte de vision profonde, les bénéfices d’Argus II à long terme dans la restauration d’une vision utile sont susceptibles de changer leur vie. Le plus enthousiasmant est peut-être la possibilité d’Argus II à augmenter la vision fonctionnelle des patients. Avec l’Argus II, certains patients peuvent effectuer des tâches qui seraient impossibles sans le dispositif. Nos travaux à Moorfields ont montré que ces changements perdurent plusieurs années après l’implantation pour certains patients et représentent pour eux un traitement stable et efficace. Ce remboursement souligne l’ambition du Gouvernement de faire du Royaume-Uni un chef de file mondial en matière d’innovation médicale. » Second Sight poursuit ses travaux novateurs avec l’objectif de restaurer la vision chez des patients souffrant de n’importe quel type de cécité incurable. La société continue ses recherches au Royaume-Uni sur la dégénérescence maculaire liée à l'âge (DMLA). En 2015, le Manchester Royal Eye Hospital en Angleterre a équipé d’implants plusieurs patients atteints de DMLA. La maladie est plus complexe que la RP. Aux États-Unis, Second Sight travaille avec l'Université de Californie Los Angeles (UCLA), qui a récemment effectué une implantation et l’activation réussies d’un stimulateur cortical visuel sur un sujet humain. Le système Argus II de Second Sight produit une stimulation électrique permettant de contourner les cellules rétiniennes mortes et de stimuler les cellules viables restantes, ce qui induit une perception visuelle chez des personnes atteintes de dégénérescence rétinienne périphérique sévère à majeure. Le dispositif Argus II fonctionne en convertissant des images capturées par une caméra vidéo miniature montée sur les lunettes du patient en une série de petites impulsions électriques transmises par liaison sans fil à un faisceau d'électrodes implantées à la surface de la rétine. Ces impulsions visent à stimuler les dernières cellules vivantes de la rétine, entraînant une perception de motifs lumineux dans le cerveau. Le patient apprend ensuite à interpréter ces motifs visuels, récupérant ainsi une certaine fonction visuelle. Argus II est la première rétine artificielle à avoir reçu une autorisation au niveau mondial. Elle est déjà disponible dans des centres approuvés au Canada, en France, en Allemagne, en Italie, aux Pays-Bas, en Arabie Saoudite, en Espagne, en Suisse, en Turquie, au Royaume-Uni et aux États-Unis. Second Sight a pour mission de développer, fabriquer et commercialiser des prothèses visuelles implantables afin de permettre à des personnes non-voyantes d’acquérir une plus grande autonomie. Second Sight développe, conçoit et commercialise le système de prothèse rétinienne Argus® II. Le recrutement des patients pour un essai clinique visant à évaluer l’innocuité et l’utilité d’Argus II chez des personnes atteintes de la forme « sèche » de dégénérescence maculaire liée à l'âge est terminé. Second Sight développe également la prothèse corticale visuelle Orion™ I visant à restaurer une vision chez des personnes dont la cécité provient de causes autres que des pathologies évitables ou curables. Le siège social américain de la société et implanté à Sylmar, en Californie, et son siège social européen est à Lausanne, en Suisse. Pour plus d’informations : www.secondsight.com. Ce communiqué de presse contient des énoncés prospectifs au sens de la Section 27A de la loi Securities Act de 1933, sous sa forme amendée, et de la Section 21E de la loi Securities Exchange and Exchange Act de 1934, sous sa forme amendée, qui sont censés être couverts par la « règle refuge » créée par ces sections. Tous les énoncés formulés dans ce communiqué qui ne sont pas basés sur des faits historiques sont des « énoncés prospectifs ». Ces énoncés peuvent être identifiés par des mots tels que « estime », « anticipe », « projette », « prévoit », « prévu », « cherche à », « pourrait », « fera », s’attend à », « a l’intention de », « pense que », « devrait » et des expressions similaires, ou leurs versions négatives, et sont également susceptibles d’être identifiés par leur contexte. Tous les énoncés traitant des performances d'exploitation, d’événements ou développements dont la survenue future est attendue ou anticipée par Second Sight sont des énoncés prospectifs. Bien que la direction ait fondé tous les énoncés prospectifs contenus dans le présent communiqué sur ses attentes actuelles, les renseignements sur lesquels sont basées lesdites attentes peuvent être amenés à changer. Les énoncés prospectifs comportent des incertitudes et des risques inhérents susceptibles de faire varier sensiblement les résultats réels par rapport à ceux indiqués dans les énoncés prospectifs en raison de divers facteurs, dont les risques et incertitudes décrits dans les sections « Facteurs de risque » et « Analyse par la direction de la situation financière et des résultats d'exploitation » de notre rapport annuel sur formulaire 10-K déposé le 11 mars 2016 et modifié le 8 août 2016, et de nos autres rapports déposés à l’occasion auprès de la SEC (Commission américaine de contrôle des opérations boursières). Nous vous conseillons vivement de tenir compte de ces risques et incertitudes lors de l’évaluation de nos énoncés prospectifs. Nous déconseillons aux lecteurs de se fier indûment à l’un quelconque de ces énoncés prospectifs, qui ne valent qu’à la date à laquelle ils sont formulés. Sauf si les lois fédérales sur les valeurs mobilières l’exigent, nous rejetons toute obligation ou engagement à publier des mises à jour ou révisions d’un quelconque énoncé prospectif formulé dans les présentes (ou ailleurs) pour refléter un quelconque changement au niveau de nos attentes à cet égard ou un quelconque changement au niveau des événements, situations ou circonstances sur lesquels un tel énoncé est basé.


News Article | December 22, 2016
Site: www.businesswire.com

SYLMAR, Calif. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (Nasdaq:EYES) (“Second Sight”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients suffering from Retinitis Pigmentosa (RP), today announced, following a positive recommendation from advisors to the UK Government’s healthcare funding authority for specialized services in England that, for the first time in the UK, the publicly-funded NHS system will fund blind patients with RP to receive treatment with the Argus® II Retinal Prosthesis System (Argus II) “bionic eye”. NHS England has announced that a selective group of severely blind patients with Retinitis Pigmentosa can have access to Argus II, the world’s first and only routinely used treatment for severe blindness. There will be two implantation centers: the Manchester Royal Eye Hospital in the north of England, and in the south, London’s Moorfields Eye Hospital. The hospitals and Second Sight will also provide follow up, rehabilitation and support to patients receiving an Argus II implant. Argus II will be funded via the Commissioning through Evaluation (CtE) program. The CtE program is especially designed for treatments that show significant promise for the future, while new clinical and patient experience data are collected within a formal evaluation program. Argus II is already reimbursed under a similar “coverage with evidence development” program in France called “Forfait Innovation” where patients have benefitted from the Argus II treatment. Will McGuire, President and CEO of Second Sight, said, “This is a major milestone for Second Sight because we are the only company able to demonstrate a favorable long-term benefit-to-risk statement up to five years after implantation for some RP patients. NHS England is known to be under significant financial pressure and also extremely selective in adopting innovative technologies – which must demonstrate sufficient value for money. We expect that this decision will be observed throughout the world by other healthcare agencies.” Professor Paulo Stanga from Manchester Royal Eye Hospital, University of Manchester and Manchester Vision Regeneration (MVR) Lab at NIHR/Wellcome Trust Manchester Clinical Research Facility, who has played a crucial role bringing the ‘bionic eye’ to patients at the NHS, said, “I’m delighted that our pioneering research has provided the evidence to support NHS England’s decision to fund the ‘bionic eye’ for the first time. I have seen first-hand how beneficial and life changing this technology has been to RP patients who are completely blind. We live in a visual world, so it is reassuring and life affirming for a person who is completely blind to regain some basic vision. This is a wonderful decision. For patients’ families, it is also a life-enhancing treatment, because it can mean less dependence for their loved ones.” Professor Lyndon da Cruz, MD, PhD, Consultant Retinal Surgeon at Moorfields Eye Hospital NHS Foundation Trust, who, with Prof. Stanga, has been championing NHS funding of the treatment for more than five years, said: “For patients with RP who have profound vision loss, the long-term benefits of the Argus II in restoring some useful vision may be life-changing. Perhaps most exciting is the potential ability of the Argus II to increase patients’ functional vision. With the Argus II, some patients can perform tasks that would not be possible without the device. Our work at Moorfields has shown that these changes last for many years after implantation for some patients and represent a stable, effective treatment for them. This funding underlines the Government’s ambition to position the UK as a global leader in medical innovation.” Second Sight continues its groundbreaking work with the aim to restore vision to patients with every type of untreatable blindness. Its UK research on age-related macular degeneration (AMD) continues. In 2015, the Manchester Royal Eye Hospital in England fitted several AMD patients with implants. This illness is more complex than RP. In the US, Second Sight is working with UCLA, recently performing the successful implantation and activation of a wireless visual cortical stimulator in a human subject. Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in individuals with severe to profound retinitis pigmentosa. The Argus II works by converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to stimulate the retina's remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to interpret these visual patterns, thereby regaining some visual function. The Argus II is the first artificial retina to receive widespread approval. It is offered at approved centers in Canada, France, Germany, Italy, the Netherlands, Saudi Arabia, Spain, Switzerland, Turkey, the United Kingdom and the US. Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight developed and manufactures the Argus® II Retinal Prosthesis System. Enrollment has been completed in a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. US Headquarters are in Sylmar, CA, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com. This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange and Exchange Act of 1934, as amended, that are intended to be covered by the 'safe harbor' created by those sections. All statements in this release that are not based on historical fact are 'forward looking statements'. These statements may be identified by words such as 'estimates', 'anticipates', 'projects', 'plans', or 'planned', 'seeks', 'may', 'will', 'expects', 'intends', 'believes', 'should' and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K as filed on March 11, 2016, as amended on August 8, 2016, and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


Muqit M.M.K.,Moorfields Eye Hospital | Stanga P.E.,Manchester Royal Eye Hospital | Stanga P.E.,University of Manchester
British Journal of Ophthalmology | Year: 2014

Aim: To describe the in vivo spatial and morphological vitreoretinal relationships associated with diabetic retinal neovascularisation using Fourier-domain optical coherence tomography (FD-OCT). Methods: Qualitative assessment of macula, retina and optic disc head FD-OCT (Topcon 3D OCT-1000) imaging of patients with treatment-naive and laser-treated proliferative diabetic retinopathy (PDR). The morphology and plane of retinal neovascularisation at the disc (NVD) and elsewhere in the retina (NVE) were examined, and the posterior vitreous relationships were evaluated. The FD-OCT characteristics of clinical versus subclinical PDR disease were correlated with conventional and wide-field Optos fundus fluorescein angiography. Results: 50 eyes of 50 patients were evaluated in this retrospective study. Retinal neovascularisation appears as a hyper-reflective complex, with NVE arising from inner retina with disruption through the internal limiting membrane to attach to the posterior hyaloid surface. FD-OCT detected subclinical hyper-reflective NVD complexes that were subvisible on colour fundus imaging. We describe retinoschisis, vitreoretinal adhesions and pegs, zones of separation, and intraretinal tractional elements in untreated PDR patients using high resolution FD-OCT. Conclusions: FD-OCT can non-invasively characterise retinal and optic nerve head neovascular complexes at different stages of the proliferative disease process. In clinical practice, FD-OCT can monitor the in vivo serial changes of retinal neovascularisation over time.


News Article | December 22, 2016
Site: www.techradar.com

Those suffering from retinitis pigmentosa, an inherited form of blindness, have been given a glimmer of hope by the UK's National Health Service. A successful trial now means that NHS England will carry out procedures to implant "bionic eyes" into ten patients from around the UK, restoring some of their sight. Five patients from the Manchester Royal Eye Hospital and five from Moorfields Eye Hospital in London will be fitted with the Argus II retinal implant in the new year, which uses a mounted camera to capture light and send a signal to the brain. It allows the wearer to discern between light levels and, in some cases, even make out large lettering. "I'm delighted that our pioneering research has provided the evidence to support NHS England's decision to fund the bionic eye for the first time in patients," said Professor Paulo Stanga from the Manchester Royal Eye Hospital. "It surpassed all of our expectations when we realised that one of the retinitis pigmentosa patients in Manchester using the bionic eye could identify large letters for the first time in his adult life." The patients will now be monitored for a year to study the long term use of the implant, which has already been trialled in cases of macular degeneration - the leading form of blindness, affecting more than 20 million people around the world.


Saha K.,Chelsea and Westminster Hospital | Leatherbarrow B.,Manchester Royal Eye Hospital
Current Opinion in Ophthalmology | Year: 2012

PURPOSE OF REVIEW: Orbital lymphangiomas present a difficult management problem for the ophthalmologist. This review offers a strategy for managing the condition. RECENT FINDINGS: There have been recent publications discussing the use of intralesional fibrin glue to aid dissection and intralesional sclerosant to shrink the lesion. We discuss the evidence for these treatments and present a case in which these treatments were combined. SUMMARY: This review highlights the classification and presents management options for orbital lymphangioma. We encourage a holistic and individualized approach to the patients, recognizing the variety of clinical manifestations that the condition can cause. In the event of surgical excision, we present the evidence for the use of intralesional fibrin glue and intralesional sclerosant, and describe using both in the same case. © 2012 Wolters Kluwer Health.


Summers C.G.,University of Minnesota | Ashworth J.L.,Manchester Royal Eye Hospital
Rheumatology | Year: 2011

Diagnosis of mucopolysaccharidosis (MPS) requires awareness of the multisystem disease manifestations and their diverse presentation in terms of time of onset and severity. Many patients with MPS remain undiagnosed for years and progressively develop irreversible pathologies, which ultimately lead to premature death. To foster timely treatment and ensure a better outcome, it is of utmost importance to recognize and evaluate the typical ocular features that present fairly early in the course of the disease in many children with MPS. These include corneal clouding, ocular hypertension/glaucoma, retinal degeneration, optic disc swelling and optic nerve atrophy. Other associations include pseudo-exophthalmos, amblyopia, strabismus and large refractive errors requiring spectacle correction. While some ocular manifestations require specialized equipment for detecting abnormalities, light sensitivity, pseudoexophthalmos and strabismus are often apparent on a routine physical examination. In addition, patients may be symptomatic from vision impairment, photosensitivity, night blindness and visual field constriction. Combined with the skeletal/joint complications and other manifestations, these ocular features are key in the differential diagnosis of children with joint abnormalities. Rheumatologists should have a high index of suspicion for MPS to facilitate early diagnosis. Referral to a geneticist, a metabolic specialist or physician who specializes in MPS can confirm the diagnosis and provide disease management. Consultation with an ophthalmologist who has expertise in MPS is also needed for thorough examination of the eyes and regular follow-up care. © The Author 2011. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.


Dharmasena A.,Manchester Royal Eye Hospital
International Journal of Ophthalmology | Year: 2014

The therapeutic effect of selenium (Se) has already been proven in thyroid disease and thyroid associated ophthalmopathy (TAO). In spite of clear scientific proof of its benefits in TAO, there appears to be no clear agreement among the clinicians regarding its optimum dose, duration of the treatment, efficacy and safety to date. In this review, the author summarises the findings of l 35 English language articles published on this subject over the past four decades from 1973 to 2013. The regulation and metabolism of thyroid hormones require a steady supply of Se and recent studies have revealed several possible mechanisms by which Se improves the severity of thyroid disease and TAO. These mechanisms include 1) inhibitory effect of HLA-DR molecule expression on thyrocytes; 2) profound reductions of thyroid stimulating hormone (TSH) receptor antibodies (TSHR-Ab) and TPO antibodies (TPO-Ab); 3) prevention of dy sregulation of cell-mediated immunity and B cell function; 4) neutralising reactive oxygen species (ROS) and inhibition of redox control processes required for the activation, differentiation and action of lymphocytes, macrophages, neutrophils, natural killer cells involved in both acute and chronic orbital inflammation in TAO; 5) inhibition of expression of pro-inflammatory cytokines and 6) inhibition of prostaglandin and leukotriene synthesis. An increased oxidative stress has been observed in both acute and chronic phases of thyroid disease with raised tissue concentrations of ROS. The benefits of Se supplementation in individuals with TAO appear to be proportionate to the degree of systemic activity of the thyroid disease. The maximal benefit of Se supplementation is therefore seen in the subjects who are hyperthy roid. Restoration of euthyroidism is one of the main goals in the management of TAO and when anti-thyroid drugs are combined with Se, the patients with Graves' disease (GD) and autoimmune thyroiditis (AIT) achieved euthyroidism faster than those treated with anti-thyroid drugs alone. Se status of normal adult humans can vary widely and Se supplementation may confer benefit only if serum Se levels are insufficient. The author recommends that serum Se levels of patients with TAO to be assessed prior to and during Se supplementation at regular intervals to avoid potential iatrogenic chronic Se overdose. © International Journal of Ophthalmology Press.


Gan W.L.,Manchester Royal Eye Hospital | Jones N.P.,Manchester Royal Eye Hospital
British Journal of Ophthalmology | Year: 2013

Aim To describe the increasing incidence of multifocal outer retinal and inner choroidal inflammation as a marker for intraocular tuberculosis in the UK, a nonendemic area. Patients and methods Retrospective case series. Results 14 patients presented with serpiginous-like choroiditis over 10 years (seven within the last 2 years). Seven of 14 patients showed evidence of exposure to tuberculosis and received antituberculous treatment. 17 of 23 eyes showed stable or improved visual acuity. All with decreased acuity had direct macular involvement at presentation. Conclusions Multifocal outer retinal and inner choroidal inflammation is a marker for intraocular tuberculosis of increasing importance, even in a nonendemic area. Originally described as 'serpiginous-like choroiditis', the lesions are multifocal, irregular in shape, very numerous, widespread, often asymmetrical and often demonstrating both active and resolved lesions simultaneously. Active lesions show contiguous extension. We recommend that every patient with SLC should undergo testing for previous exposure to tuberculosis, and undergo antituberculous treatment if lesions are progressive and sight-threatening.


Muqit M.M.,Manchester Royal Eye Hospital
Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye | Year: 2010

In this prospective study, the authors report fourier-domain optical coherence tomography (FD-OCT) imaging of gas-inner retinal tamponade following surgery for full-thickness macular hole and evaluate postoperative posturing based on FD-OCT findings. Patients underwent FD-OCT 1 day after pars plana vitrectomy, internal limiting membrane peel, and gas injection. Three-dimensional FD-OCT and high-resolution line scans demonstrated gas-inner retinal tamponade across the macula with the apex of tamponade located at the fovea. Inner and outer retina landmarks could be accurately identified along the curvature of the eye using FD-OCT in x-, y-, and z-planes. No patients required face-down positioning postoperatively based on FD-OCT findings. Satisfactory gas-inner retinal tamponade with 75% fill of any gas agent in the upright position was observed. Full-thickness macular hole closure was successful in 90% at 1 day, 2 weeks, and 12 weeks postoperatively. These FD-OCT findings may support decisions to not require face-down positioning postoperatively. Copyright 2010, SLACK Incorporated.

Loading Manchester Royal Eye Hospital collaborators
Loading Manchester Royal Eye Hospital collaborators